← Leaderboards
Tong Zhou
University Of Alabama At Birmingham
$5,746,468
Attributed
$5,746,468
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2006–14$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$5,746,468 · 5
By mechanism
R01$3,347,810 · 2
P50$1,657,620 · 1
P30$395,315 · 1
R21$345,723 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Selvarangan Ponnazhagan$11,274,357
- Steven L Carroll$9,156,638
- Donald J Buchsbaum$5,699,601
- Scott Michael Wilson$6,208,421
- G. Yancey Gillespie$5,456,344
Others in their field
Top investigators on “Apoptosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$49,205,802
- Jay A Nelson · Oregon Health & Science University$45,942,124
- John C Reed · University Of Texas Md Anderson Can Ctr$34,437,189
- John A Tainer · Scripps Research Institute$30,637,655
- Henry Shelton Earp · Univ Of North Carolina Chapel Hill$28,872,594
- John D Minna · University Of Texas Sw Med Ctr/Dallas$27,317,167
Research focus
ApoptosisMediatingResistanceResponseCancer Cell LineReceptorTreatment EfficacySignal TransductionRegulationTumorPlayComplexCancer CellNeoplastic CellClinical TrialsMonoclonal AntibodiesDeath DomainBoxingChemotherapeutic AgentMalignant NeoplasmsCytotoxicityCessation Of LifeProgramsHepatocyte
Grant awards (21)
Novel Anti-HER3 Strategy for Pancreatic Cancer$154,540
R21 · FY2014 · CA · contact PI
Novel Anti-HER3 Strategy for Pancreatic Cancer$191,183
R21 · FY2013 · CA · contact PI
Death Receptor-mediated Apoptosis and Therapy Strategies in Ovarian Cancer$444,659
R01 · FY2011 · CA · contact PI
DR5 Antibody Therapy for Breast Cancer$325,054
P50 · FY2011 · CA · contact PI
Death Receptor-mediated Apoptosis and Therapy Strategies in Ovarian Cancer$459,161
R01 · FY2010 · CA · contact PI
DR5 Antibody Therapy for Breast Cancer$341,952
P50 · FY2010 · CA · contact PI
Role of DDX3 in DR5-Mediated Apoptosis$200,618
R01 · FY2010 · CA · contact PI
Death Receptor-mediated Apoptosis and Therapy Strategies in Ovarian Cancer$450,917
R01 · FY2009 · CA · contact PI
DR5 Antibody Therapy for Breast Cancer$341,731
P50 · FY2009 · CA · contact PI
Role of DDX3 in DR5-Mediated Apoptosis$204,869
R01 · FY2009 · CA · contact PI
Role of DDX3 in DR5-Mediated Apoptosis$200,618
R01 · FY2009 · CA · contact PI
Death Receptor-mediated Apoptosis and Therapy Strategies in Ovarian Cancer$439,913
R01 · FY2008 · CA · contact PI
DR5 Antibody Therapy for Breast Cancer$322,929
P50 · FY2008 · CA · contact PI
Role of DDX3 in DR5-Mediated Apoptosis$200,618
R01 · FY2008 · CA · contact PI
Death Receptor-mediated Apoptosis and Therapy Strategies in Ovarian Cancer$339,209
R01 · FY2007 · CA · contact PI
DR5 Antibody Therapy for Breast Cancer$325,954
P50 · FY2007 · CA · contact PI
Role of DDX3 in DR5-Mediated Apoptosis$200,618
R01 · FY2007 · CA · contact PI
Role of DDX3 in DR5-Mediated Apoptosis$206,610
R01 · FY2006 · CA · contact PI
PILOT--INDUCTION OF T CELL TOLERANCE TO ANTIVIRAL VECTOR$165,355
P30 · FY2002 · DK
PILOT--INDUCTION OF T CELL TOLERANCE TO ANTIVIRAL VECTOR$165,355
P30 · FY2001 · DK
PILOT--INDUCTION OF T CELL TOLERANCE TO ANTIVIRAL VECTOR$64,605
P30 · FY2000 · DK